89biologo.png
89bio Announces Positive Topline Results from its Phase 1b/2a Trial of BIO89-100 in NASH
September 14, 2020 07:01 ET | 89bio, Inc.
All dose groups achieved statistically significant reductions in liver fat, with relative reductions of up to 60% versus baseline and up to 70% versus placebo     Favorable safety and...
89biologo.png
89bio to Announce Topline Results from Phase 1b/2a Study of BIO89-100 in NASH
September 13, 2020 19:53 ET | 89bio, Inc.
SAN FRANCISCO, Sept. 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB) today announced that the company plans to share topline safety, tolerability and efficacy data from its Phase 1b/2a study...
89biologo.png
89bio Initiates Phase 2 Trial of BIO89-100 in Patients with Severe Hypertriglyceridemia
September 03, 2020 08:30 ET | 89bio, Inc.
SAN FRANCISCO, Sept. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 13, 2020 16:05 ET | 89bio, Inc.
- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in Late Q3 to Early Q4 - - BIO89-100’s Phase 2 SHTG trial is expected to be initiated in Q3 - SAN FRANCISCO, Aug. 13, 2020...
89biologo.png
89bio to Present at Upcoming Investor Conferences
August 03, 2020 16:05 ET | 89bio, Inc.
SAN FRANCISCO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Closing of Upsized Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
July 13, 2020 10:17 ET | 89bio, Inc.
SAN FRANCISCO, July 13, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Pricing of Upsized Public Offering of Common Stock
July 07, 2020 21:30 ET | 89bio, Inc.
SAN FRANCISCO, July 07, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Announces Proposed Public Offering of Common Stock
July 06, 2020 06:30 ET | 89bio, Inc.
SAN FRANCISCO, July 06, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Appoints Veteran Finance Executive Lota Zoth to Board of Directors
June 04, 2020 08:00 ET | 89bio, Inc.
SAN FRANCISCO, June 04, 2020 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for...
89biologo.png
89bio Reports First Quarter 2020 Financial Results and Provides Corporate Update
May 13, 2020 16:05 ET | 89bio, Inc.
- Topline results from BIO89-100’s Phase 1b/2a NASH trial are expected in 2H20 - - Announces FDA Clearance of BIO89-100 IND Application for SHTG - SAN FRANCISCO, May 13, 2020 (GLOBE NEWSWIRE)...